VOTRIENT (pazopanib), tyrosine kinase inhibitor

TRANSPARENCY COMMITTEE OPINION

Opinions on drugs - Posted on Feb 03 2016

Réévaluation SMR

VOTRIENT has Marketing Authorisation in the first-line treatment of advanced renal cell carcinoma.
It does not provide any clinical benefit in the management of this type of cancer.
Its role in the therapeutic strategy is as first intention.

Substantial

Therapeutic use

Évaluation des médicaments

All our publications

My account